Emplicure interim report January to September 2021 – building a strong team and a foundation for growth

  • News

Following this summer’s new share issue and subsequent IPO, we are well equipped. The focus of the third quarter has been on shifting up, and driving the development of the company’s two main projects; Empli03, our drug candidate for chronic pain, and Amp01, our oral tobacco-free nicotine product in the form of dry, white pouches as a consumer product. Both projects are developed on our own bioceramic and patented technologies and platforms.

GET STARTED

Do you want to know more?

Contact us today.